$CRYM
Cryomass Technologies, Inc.

2022 Q4 Form 10-Q Financial Statement

#000121390022071328 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $4.948M $496.7K $830.0K
YoY Change 359.17% -40.15% 23.88%
% of Gross Profit
Research & Development $0.00 $2.031K
YoY Change
% of Gross Profit
Depreciation & Amortization $91.50K $21.84K $21.83K
YoY Change 319.15% 0.05%
% of Gross Profit
Operating Expenses $5.514M $1.254M $2.056M
YoY Change 139.51% -39.03% 74.28%
Operating Profit -$5.514M -$1.254M -$2.056M
YoY Change 139.51% -39.03% 74.28%
Interest Expense -$119.4K $25.41K -$567.4K
YoY Change -88.48% -104.48% 372.86%
% of Operating Profit
Other Income/Expense, Net $25.41K -$567.4K
YoY Change -104.48%
Pretax Income -$5.633M -$1.228M -$2.624M
YoY Change 68.72% -53.18% 101.84%
Income Tax -$21.79K $0.00
% Of Pretax Income
Net Earnings -$5.612M -$1.228M -$2.374M
YoY Change -15.86% -48.25% -60.04%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.02
Diluted Earnings Per Share -$0.03 -$0.01 -$19.96K
COMMON SHARES
Basic Shares Outstanding 202.5M shares 201.5M shares 118.9M shares
Diluted Shares Outstanding 202.0M shares 118.9M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.016M $3.130M $237.6K
YoY Change -65.08% 1217.51% -61.06%
Cash & Equivalents $2.016M $3.130M $237.6K
Short-Term Investments
Other Short-Term Assets $150.4K $136.6K $7.431M
YoY Change -80.14% -98.16% 4.82%
Inventory
Prepaid Expenses $128.7K $136.6K
Receivables $540.0K
Other Receivables $281.8K
Total Short-Term Assets $2.166M $3.266M $8.491M
YoY Change -66.82% -61.53% 1.2%
LONG-TERM ASSETS
Property, Plant & Equipment $525.9K $349.6K $135.0K
YoY Change 133.71% 158.95%
Goodwill $1.190M $1.190M
YoY Change 0.0%
Intangibles $3.981M
YoY Change
Long-Term Investments $10.30M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $5.696M $9.785M $5.385M
YoY Change -37.08% 81.69%
TOTAL ASSETS
Total Short-Term Assets $2.166M $3.266M $8.491M
Total Long-Term Assets $5.696M $9.785M $5.385M
Total Assets $7.863M $13.05M $13.88M
YoY Change -49.54% -5.95% 65.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.288M $1.235M $3.125M
YoY Change -31.52% -60.48% 95.29%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $1.744M
YoY Change -100.0% 190.69%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.288M $1.235M $5.547M
YoY Change -31.55% -77.73% 49.1%
LONG-TERM LIABILITIES
Long-Term Debt $2.000M $2.000M $4.132M
YoY Change 1029.43% -51.6% 20562.4%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $2.000M $2.000M $4.132M
YoY Change 1029.43% -51.6% 20562.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.288M $1.235M $5.547M
Total Long-Term Liabilities $2.000M $2.000M $4.132M
Total Liabilities $3.288M $3.235M $9.694M
YoY Change 59.67% -66.63% 158.51%
SHAREHOLDERS EQUITY
Retained Earnings -$39.01M -$33.40M
YoY Change 36.46%
Common Stock $202.7K $202.5K
YoY Change 2.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.574M $9.816M $4.182M
YoY Change
Total Liabilities & Shareholders Equity $7.863M $13.05M $13.88M
YoY Change -49.54% -5.95% 65.39%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$5.612M -$1.228M -$2.374M
YoY Change -15.86% -48.25% -60.04%
Depreciation, Depletion And Amortization $91.50K $21.84K $21.83K
YoY Change 319.15% 0.05%
Cash From Operating Activities -$913.5K -$885.0K -$1.021M
YoY Change -63.9% -13.36% 21.6%
INVESTING ACTIVITIES
Capital Expenditures $222.1K -$33.86K -$135.0K
YoY Change -346.74% -74.92%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$56.56K
YoY Change -100.0% -100.0% 465.6%
Cash From Investing Activities -$222.1K -$33.86K -$191.6K
YoY Change 58.63% -82.32% 1815.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.87K 1.861M 1.019M
YoY Change -99.73% 82.53% 19.92%
NET CHANGE
Cash From Operating Activities -913.5K -885.0K -1.021M
Cash From Investing Activities -222.1K -33.86K -191.6K
Cash From Financing Activities 21.87K 1.861M 1.019M
Net Change In Cash -1.114M 941.7K -193.8K
YoY Change -120.12% -586.01% -180543536438879500.0%
FREE CASH FLOW
Cash From Operating Activities -$913.5K -$885.0K -$1.021M
Capital Expenditures $222.1K -$33.86K -$135.0K
Free Cash Flow -$1.136M -$851.1K -$886.5K
YoY Change -53.47% -3.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses
DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
usd
us-gaap Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses
DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
usd
CY2022Q3 crym Common Stock To Be Issued
CommonStockToBeIssued
usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses
DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
usd
CY2021Q3 us-gaap Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses
DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
usd
dei Document Type
DocumentType
10-Q
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56155
dei Entity Registrant Name
EntityRegistrantName
CRYOMASS TECHNOLOGIES INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5051728
dei Entity Address Address Line1
EntityAddressAddressLine1
1001 Bannock Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 612
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80204
dei City Area Code
CityAreaCode
303
dei Local Phone Number
LocalPhoneNumber
416-7208
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
202526205 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3129736 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5772839 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
136637 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
757383 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
3266373 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
6530222 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Noncurrent
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent
4218831 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Noncurrent
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent
3600000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
349586 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
225000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4026291 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4038600 usd
CY2022Q3 us-gaap Goodwill
Goodwill
1190000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
1190000 usd
CY2022Q3 us-gaap Assets
Assets
13051081 usd
CY2021Q4 us-gaap Assets
Assets
15583822 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1235004 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1882419 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1235004 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1882419 usd
CY2022Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
2000000 usd
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
177083 usd
CY2022Q3 us-gaap Liabilities
Liabilities
3235004 usd
CY2021Q4 us-gaap Liabilities
Liabilities
2059502 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
202526205 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
202526205 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
196949801 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
196949801 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
202528 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
196950 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43013522 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
41916207 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33399973 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28588837 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
9816077 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13524320 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13051081 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15583822 usd
CY2022Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
733233 usd
CY2021Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1204621 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1534885 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
2004417 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
306037 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
489797 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
839818 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2865604 usd
CY2022Q3 us-gaap Legal Fees
LegalFees
190693 usd
CY2021Q3 us-gaap Legal Fees
LegalFees
340226 usd
us-gaap Legal Fees
LegalFees
2337143 usd
us-gaap Legal Fees
LegalFees
797772 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
21832 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
21832 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
65495 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21832 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2031 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20518 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
1253826 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
2056476 usd
us-gaap Operating Expenses
OperatingExpenses
4797859 usd
us-gaap Operating Expenses
OperatingExpenses
5689625 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1253826 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2056476 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4797859 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5689625 usd
CY2022Q3 crym Non Operating Interest Expense
NonOperatingInterestExpense
19636 usd
CY2021Q3 crym Non Operating Interest Expense
NonOperatingInterestExpense
590601 usd
crym Non Operating Interest Expense
NonOperatingInterestExpense
90894 usd
crym Non Operating Interest Expense
NonOperatingInterestExpense
1152858 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
45049 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
23170 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-4811135 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6795775 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
77618 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
46708 usd
CY2021Q3 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
-250092 usd
us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
-605394 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1228413 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25413 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-567431 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13276 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1106150 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1228413 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2623907 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4811135 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6795775 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-1228413 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-2623907 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2373815 usd
us-gaap Net Income Loss
NetIncomeLoss
-4811135 usd
us-gaap Net Income Loss
NetIncomeLoss
-6190381 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1228413 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2373815 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4811135 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6190381 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.06
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
201998206 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
118939488 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
203440055 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107846167 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3605294 usd
CY2021Q1 crym Share Issuance
ShareIssuance
110000 usd
CY2021Q1 crym Stockbased Compensation Options
StockbasedCompensationOptions
250817 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1046927 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2919184 usd
CY2021Q2 crym Share Issuance
ShareIssuance
202 usd
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1804500 usd
crym Accounts Payable And Accrued Expense
AccountsPayableAndAccruedExpense
647415 usd
CY2021Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
900701 usd
CY2021Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
508402 usd
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
57500 usd
CY2021Q2 crym Stockbased Compensation Options
StockbasedCompensationOptions
190026 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
710202 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
391958 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
888371 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2769639 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
5601407 usd
CY2021Q3 crym Share Issuance
ShareIssuance
199798 usd
CY2021Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
240487 usd
CY2021Q3 crym Share Issuance For Interest Payment On Note Payable
ShareIssuanceForInterestPaymentOnNotePayable
-23409 usd
CY2021Q3 crym Stockbased Compensation Options
StockbasedCompensationOptions
68628 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
258003 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
123805 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
40408 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2373815 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4182130 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13524320 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
240625 usd
CY2022Q1 crym Stockbased Compensation Options
StockbasedCompensationOptions
140815 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2152305 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11753455 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66151 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
240626 usd
CY2022Q2 crym Stockbased Compensation Options
StockbasedCompensationOptions
69095 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1430418 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10698909 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
65626 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
214134 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
23409 usd
CY2022Q3 crym Stockbased Compensation Options
StockbasedCompensationOptions
89230 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1228413 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
9816077 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4811135 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6795775 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
72917 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
539692 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
65495 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21832 usd
us-gaap Share Based Compensation
ShareBasedCompensation
299140 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2400976 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
546876 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
291096 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-620746 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2722891 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-347204 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3853376 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
57129 usd
crym Accounts Payable And Accrued Expense
AccountsPayableAndAccruedExpense
-876417 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3853376 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3070095 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1000000 usd
crym Payoff Of Cryo Cann Loan Agreement At Closing
PayoffOfCryoCannLoanAgreementAtClosing
1247684 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
618831 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
124586 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
135000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
53186 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-796603 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2382684 usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-280561 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-796603 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2663245 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
237590 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
256876 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
320000 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-40668 usd
crym Proceeds From Notes Payable Current
ProceedsFromNotesPayableCurrent
1750000 usd
crym Proceeds From Notes Payable Current
ProceedsFromNotesPayableCurrent
4900000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
281771 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2006876 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5135151 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
505902 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2006876 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5641053 usd
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-2643103 usd
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
29576 usd
us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
-121863 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5772839 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
329839 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3129736 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
237552 usd
us-gaap Interest Paid Net
InterestPaidNet
16592 usd
us-gaap Interest Paid Net
InterestPaidNet
283330 usd
crym Common Stock Issued Pursuant To Vesting Of Restricted Stock Units
CommonStockIssuedPursuantToVestingOfRestrictedStockUnits
30000 usd
crym Common Stock Issued Pursuant To Vesting Of Restricted Stock Units
CommonStockIssuedPursuantToVestingOfRestrictedStockUnits
2851103 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. Nature of the Business</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cryomass Technologies Inc (“Cryomass Technologies” or the “Company”) designs, manufactures and is developing the strategy to commercialize patented cryo-mechanical systems for the harvesting and refinement of hemp, cannabis, and potentially other high value crops such as hops. The system exploits CryoMass’s U.S.-patented process for the controlled application of liquid nitrogen to stabilize and separate the structural elements of gross plant material. The device currently under development can be operated at a cultivation site or be installed at a processing facility and is being optimized for the collection of fully intact hemp and cannabis trichomes. The first functional “beta” machine has completed field testing. The Company is currently negotiating a license and lease arrangement with a third party to deploy multiple CryoMass trichome separation units at the prospective partner’s facility in California and other locations, with the intention of starting commercial operations shortly thereafter.</p>
CY2021Q4 us-gaap Variable Interest Difference Between Carrying Amount And Maximum Exposure
VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure
3600000 usd
CY2021 us-gaap Variable Interest Entity Qualitative Or Quantitative Information Date Involvement Began1
VariableInterestEntityQualitativeOrQuantitativeInformationDateInvolvementBegan1
2023-12-31
CY2021Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.12 pure
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
24500000 shares
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
0.4
CY2022Q3 crym Working Capital
WorkingCapital
2031369 usd
CY2022Q3 us-gaap Cash
Cash
3129736 usd
us-gaap Retail Land Sales Estimated Cost Of Major Improvements
RetailLandSalesEstimatedCostOfMajorImprovements
4000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6600000 usd
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
100000 usd
crym Facility Limit
FacilityLimit
10000000 usd
crym Cash For Operating Activities
CashForOperatingActivities
3853376 usd
us-gaap Malpractice Loss Contingency Claims Incurred Net
MalpracticeLossContingencyClaimsIncurredNet
4811135 usd
CY2022Q3 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
33399973 usd
CY2021Q3 crym Debt Instrument Amortized Discount
DebtInstrumentAmortizedDiscount
320049 usd
crym Debt Instrument Amortized Discount
DebtInstrumentAmortizedDiscount
508831 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reclassifications</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain items in the interim condensed consolidated financial statements were reclassified from prior periods for presentation purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Additionally, the company entered into a $3,600,000 loan receivable in conjunction with the disposal of discontinued operations at the end of 2021, which is backed by the assets of the discontinued operations, should the borrower default. Aside from these items, the Company does not believe it is exposed to any unusual credit risk.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021 us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
3600000 usd
crym Income Taxes Description
IncomeTaxesDescription
In accordance with ASC 740-10, for those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, our policy will be to record the largest amount of tax benefit that is more likely than not to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit will be recognized in the condensed consolidated financial statements.
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
928779 usd
crym Conversion Of Warrants
ConversionOfWarrants
515763 usd
CY2022Q3 us-gaap Notes Payable
NotesPayable
1444542 usd
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
6600000 usd
CY2021 us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
3600000 usd
CY2022Q1 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
620000 usd
crym Unvested Of Shares Restricted Stock Potentially Dilutive Securities Outstanding
UnvestedOfSharesRestrictedStockPotentiallyDilutiveSecuritiesOutstanding
1313860 shares
crym Unvested Of Shares Restricted Stock Potentially Dilutive Securities Outstanding
UnvestedOfSharesRestrictedStockPotentiallyDilutiveSecuritiesOutstanding
2185003 shares
CY2021Q2 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3500000 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Share Based Compensation Gross
StockIssuedDuringPeriodSharesShareBasedCompensationGross
10000000 shares
CY2021Q4 crym Promissory Note Issued
PromissoryNoteIssued
1252316 usd
CY2021Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
2500000 usd
CY2021Q3 us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
2373815 usd
us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
7407987 usd
CY2021Q1 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.936 pure
CY2021Q3 us-gaap Extinguishment Of Debt Gain Loss Per Share Net Of Tax
ExtinguishmentOfDebtGainLossPerShareNetOfTax
0.02
us-gaap Extinguishment Of Debt Gain Loss Per Share Net Of Tax
ExtinguishmentOfDebtGainLossPerShareNetOfTax
0.06
CY2021Q3 us-gaap Debt Instrument Repurchase Date
DebtInstrumentRepurchaseDate
2021-10-19
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
349586 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
225000 usd
crym Carrying Value Of Goodwill
CarryingValueOfGoodwill
1190000 usd
CY2021 crym Carrying Value Of Goodwill
CarryingValueOfGoodwill
1190000 usd
CY2022Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
4135449 usd
CY2022Q3 crym Indefinite Lived Intangible Assets Accumulated Amortization Excluding Goodwill
IndefiniteLivedIntangibleAssetsAccumulatedAmortizationExcludingGoodwill
-109158 usd
CY2022Q3 crym Indefinitelived Intangible Assets Impairment
IndefinitelivedIntangibleAssetsImpairment
4026291 usd
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
4082263 usd
CY2021Q4 crym Indefinite Lived Intangible Assets Accumulated Amortization Excluding Goodwill
IndefiniteLivedIntangibleAssetsAccumulatedAmortizationExcludingGoodwill
-43663 usd
CY2021Q4 crym Indefinitelived Intangible Assets Impairment
IndefinitelivedIntangibleAssetsImpairment
4038600 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21832 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
65495 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21832 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21832 usd
CY2022Q3 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
2000000 usd
CY2022Q3 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.12 pure
CY2020Q3 us-gaap Debt Instrument Description
DebtInstrumentDescription
The 1) convertible note had a face value of $250,000, matured August 1, 2022, and accrues interest at 8% per annum.
CY2021Q4 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
177083 usd
CY2021Q4 us-gaap Convertible Debt
ConvertibleDebt
250000 usd
CY2022Q3 us-gaap Subordinated Borrowing Due Date
SubordinatedBorrowingDueDate
2024-10-01
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
72917 usd
CY2021Q4 us-gaap Long Term Debt Maturity Date
LongTermDebtMaturityDate
2022-08-01
CY2021Q1 us-gaap Debt Instrument Repurchase Date
DebtInstrumentRepurchaseDate
2021-04-27
CY2021Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
225000 usd
CY2021Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.15 pure
CY2021Q1 us-gaap Debt Instrument Repurchase Date
DebtInstrumentRepurchaseDate
2021-05-07
CY2021Q3 us-gaap Derivative Fixed Interest Rate
DerivativeFixedInterestRate
0.12 pure
CY2021Q3 crym Loans Agreement
LoansAgreement
300000 usd
CY2021Q3 us-gaap Short Term Debt Percentage Bearing Fixed Interest Rate
ShortTermDebtPercentageBearingFixedInterestRate
0.9123 pure
CY2021Q3 crym Debt Instruments Maturity Date
DebtInstrumentsMaturityDate
May 27, 2021
crym Note Receivable Issued Amount
NoteReceivableIssuedAmount
281771 usd
CY2021Q3 crym Loan Agreement
LoanAgreement
237590 usd
CY2021Q4 us-gaap Accounts Payable Interest Bearing Interest Rate
AccountsPayableInterestBearingInterestRate
0.14 pure
CY2021Q4 crym Excess Stock Shares Issued1
ExcessStockSharesIssued1
250000 shares
CY2021Q4 us-gaap Memberships In Exchanges Owned
MembershipsInExchangesOwned
50000 usd
CY2021Q2 crym Issuance Of Common Stock Shares
IssuanceOfCommonStockShares
10000000 shares
CY2021Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
6903172 shares
CY2021Q2 crym Agreements Shares
AgreementsShares
2500000 shares
CY2021Q2 crym Share Exchange For Services
ShareExchangeForServices
633125 shares
CY2021Q3 crym Common Stock Shares
CommonStockShares
798414 shares
CY2021Q3 us-gaap Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares
StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
633707 shares
CY2021Q3 crym Interest Rate
InterestRate
92127 shares
CY2021Q4 crym Common Stock Shares
CommonStockShares
50700000 shares
CY2021Q4 crym Common Stock In Exchange For Services
CommonStockInExchangeForServices
1570501 shares
CY2021Q4 crym Common Stock In Exchange For Extinguishment Of Debt
CommonStockInExchangeForExtinguishmentOfDebt
24621119 shares
CY2022Q1 crym Common Stock Shares
CommonStockShares
458334 shares
CY2022Q1 crym Common Stock In Exchange For Services
CommonStockInExchangeForServices
550000 shares
CY2022Q1 crym Common Stock In Exchange For Extinguishment Of Debt
CommonStockInExchangeForExtinguishmentOfDebt
185529 shares
CY2022Q1 crym Common Stock Shares
CommonStockShares
1000000 shares
CY2022Q2 crym Share Exchange For Services
ShareExchangeForServices
687501 shares
CY2022Q2 crym Common Stock Shares
CommonStockShares
1000000 shares
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod
220500 shares
CY2022Q3 crym Share Exchange For Services
ShareExchangeForServices
416667 shares
CY2022Q3 crym Common Stock Shares
CommonStockShares
1000000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
150000 shares
CY2022Q3 crym Interest Payment Paid In Cash
InterestPaymentPaidInCash
92127 shares
CY2021Q4 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstandingNumber
0.45
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1469511 shares
CY2022Q1 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Grant In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueGrantInPeriod
0.27
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1735529 shares
CY2021Q4 crym Share Based Compensation Arrangement By Share Based Restricted Stock Payment Award Number
ShareBasedCompensationArrangementByShareBasedRestrictedStockPaymentAwardNumber
2200003 shares
CY2022Q1 crym Share Based Compensation Arrangement By Share Based Payment Award Option Vested Weighted Average Grants Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedWeightedAverageGrantsDateFairValue
0.49
CY2022Q1 crym Share Based Compensation Arrangement By Share Based Restricted Stock Payment Award Number
ShareBasedCompensationArrangementByShareBasedRestrictedStockPaymentAwardNumber
1933985 shares
CY2022Q1 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstandingNumber
0.27
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
510000 shares
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Grant In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueGrantInPeriod
0.35
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1135000 shares
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Payment Award Option Vested Weighted Average Grants Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedWeightedAverageGrantsDateFairValue
0.28
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50000 shares
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Averages Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAveragesGrantDateFairValue
0.17
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Restricted Stock Payment Award Number
ShareBasedCompensationArrangementByShareBasedRestrictedStockPaymentAwardNumber
1258985 shares
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstandingNumber
0.2
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
69875 shares
CY2022Q3 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Grant In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueGrantInPeriod
0.26
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
15000 shares
CY2022Q3 crym Share Based Compensation Arrangement By Share Based Payment Award Option Vested Weighted Average Grants Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedWeightedAverageGrantsDateFairValue
0.2
CY2022Q3 crym Share Based Compensation Arrangement By Share Based Restricted Stock Payment Award Number
ShareBasedCompensationArrangementByShareBasedRestrictedStockPaymentAwardNumber
1313860 shares
CY2022Q3 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstandingNumber
0.3
CY2022Q3 us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
3000 usd
us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
1168600 usd
CY2021Q3 crym Fair Value Of Rs Us Vested
FairValueOfRSUsVested
0 usd
crym Fair Value Of Rs Us Vested
FairValueOfRSUsVested
2851102 usd
crym Unrecognized Stock Based Compensation
UnrecognizedStockBasedCompensation
203224 usd
CY2021Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1000000 shares
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
5000000 shares
CY2021Q4 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
73950000 shares
CY2021 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.4
CY2022Q3 crym Warrant Share Issued
WarrantShareIssued
220500 shares
crym Warrant Share Issued
WarrantShareIssued
220500 shares
CY2022Q3 crym Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.3
CY2022Q3 crym Fair Value Of Additional Paid In Capital
FairValueOfAdditionalPaidInCapital
1867960 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
crym Other Lease Term
OtherLeaseTerm
P12M
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
16190 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
46706 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
0 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
495360 usd
CY2022Q3 crym Present Value Of Liabilities Increased Decreased By Business Acquisition
PresentValueOfLiabilitiesIncreasedDecreasedByBusinessAcquisition
0 usd
CY2021Q3 crym Present Value Of Liabilities Increased Decreased By Business Acquisition
PresentValueOfLiabilitiesIncreasedDecreasedByBusinessAcquisition
150259 usd
crym Present Value Of Liabilities Increased Decreased By Business Acquisition
PresentValueOfLiabilitiesIncreasedDecreasedByBusinessAcquisition
0 usd
crym Present Value Of Liabilities Increased Decreased By Business Acquisition
PresentValueOfLiabilitiesIncreasedDecreasedByBusinessAcquisition
363707 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
0 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
169326 usd
CY2022Q4 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
10200000 usd
CY2022Q4 crym Net Revenue Percentage
NetRevenuePercentage
0.50 pure
CY2022Q4 crym Agreement Term
AgreementTerm
P5Y
CY2022Q3 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
usd
crym Payoff Of Cryo Cann Loan Agreement At Closing
PayoffOfCryoCannLoanAgreementAtClosing
usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
usd
us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2022Q1 crym Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Averages Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAveragesGrantDateFairValue
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001533030

Files In Submission

Name View Source Status
0001213900-22-071328-index-headers.html Edgar Link pending
0001213900-22-071328-index.html Edgar Link pending
0001213900-22-071328.txt Edgar Link pending
0001213900-22-071328-xbrl.zip Edgar Link pending
crym-20220930.xsd Edgar Link pending
f10q0922ex31-1_cryomasstech.htm Edgar Link pending
f10q0922ex31-2_cryomasstech.htm Edgar Link pending
f10q0922ex32-1_cryomasstech.htm Edgar Link pending
f10q0922ex32-2_cryomasstech.htm Edgar Link pending
f10q0922_cryomasstech.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
crym-20220930_def.xml Edgar Link unprocessable
crym-20220930_lab.xml Edgar Link unprocessable
crym-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0922_cryomasstech_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
crym-20220930_cal.xml Edgar Link unprocessable